Ekso Bionics (EKSO) – Research Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for Ekso Bionics (NASDAQ: EKSO):

• 8/1/2022 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/29/2022 – Ekso Bionics had its price target lowered by analysts at HC Wainwright from $11.00 to $9.00. They now have a “buy” rating on the stock.
• 7/24/2022 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/16/2022 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/8/2022 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 6/30/2022 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 6/22/2022 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 6/14/2022 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 6/6/2022 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

Ekso Bionics Price Performance

Shares of EKSO stock opened at $1.90 on Friday. The stock’s fifty day moving average is $1.79 and its 200-day moving average is $2.23. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.48 and a current ratio of 8.16. The stock has a market capitalization of $24.75 million, a PE ratio of -1.92 and a beta of 1.94. Ekso Bionics Holdings, Inc. has a 52 week low of $1.54 and a 52 week high of $5.41.

Ekso Bionics (NASDAQ:EKSO – Get Rating) last posted its quarterly earnings results on Thursday, July 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. Ekso Bionics had a negative return on equity of 35.11% and a negative net margin of 94.39%. During the same period in the previous year, the business earned ($0.26) EPS. Equities research analysts expect that Ekso Bionics Holdings, Inc. will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently bought a new stake in Ekso Bionics stock. Essex Investment Management Co. LLC purchased a new position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Get Rating) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 167,645 shares of the company’s stock, valued at approximately $484,000. Essex Investment Management Co. LLC owned 1.31% of Ekso Bionics at the end of the most recent reporting period. Institutional investors own 14.65% of the company’s stock.

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.

Further Reading

• Get a free copy of the StockNews.com research report on Ekso Bionics (EKSO)
• Is It Time to Take a Ride on Cedar Fair Stock?
• Time To Take A Serious Look At Nikola Stock As Production Starts
• These Are The Top Insider Buying Stocks For July
• Chipotle Mexican Grill Or Shake Shak? Which Is The Tastier Play 
• Activision Blizzard Banks On A Flurry Of New Content 

Want More Great Investing Ideas?